Allergan Patents Won’t Undergo PTAB Review Following Licensing Deal

shot by IP News Shots / 6:32 pm on 23 February, 2021

The Patent Trial and Appeal Board (PTAB) has decided not to review six skin filler patents belonging to Allergan PLC challenged by Prollenium US Inc. after the two parties entered a licensing agreement. Even though the board decided not to review the patents, it voiced scepticism on their validity. With the signing of the licensing agreement, the two parties have also ended all litigations with regard to the patents at the US District Court for the District of Delaware.

Read More at: https://www.law360.com/lifesciences/articles/1357293/allergan-patents-spared-from-ptab-review-in-settlement

Industry: Pharmaceuticals | Type of IP: Litigations